Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity

• Age \> 18 years

• Histologically confirmed malignancy for which platinum-based chemotherapy on a 21 day cycle or 14 day cycle is being recommended.

• Disease state:

‣ Stage I of the trial: newly diagnosed disease for which neoadjuvant or adjuvant chemotherapy is planned in the curative setting, or metastatic disease.

⁃ Stage II of the trial: Measurable disease by RECIST criteria must be present for all subjects in the randomized component of the trial- if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy.

• Prior chemotherapy

‣ Stage I: subjects may have already received no more than 2 cycle of platinum-based chemotherapy, but should not have received other prior chemotherapy regimens with the exception of patients with metastatic disease who received neoadjuvant or adjuvant chemotherapy and that chemotherapy was completed \> 6 months prior to enrollment.

⁃ Stage II: subjects must have received no prior chemotherapy regimens for metastatic disease, and no more than 2 cycles of their current platinum chemotherapy regimen for metastatic disease. They may have received prior neoadjuvant or adjuvant chemotherapy, provided such therapy was completed \>6 months prior to enrollment.

• Prior Radiotherapy is allowed, provided at least 2 weeks have elapsed from completion of radiotherapy to initiation of protocol treatment.

• BMI \> 18.5

• ECOG performance status 0-1

• Adequate renal function (Creatinine \<1.25 ULIN or calculated creatinine clearance \> 50 ml/min)

• Premenopausal women must have a negative pregnancy test and must agree to use barrier contraception throughout the study period.